Leukemia drug trial pulled before it even started
NCT ID NCT06522373
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a very early (Phase 1) study to test the safety of a new drug called MT-0169 in people with certain types of acute leukemia (AML or T-ALL) that had come back or not responded to treatment. The drug was given through a vein. However, the study was withdrawn before any patients were enrolled, so no results are available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- MT-0169 (given by vein)
- What this could lead to
- If it works, this could point toward a new treatment option for certain types of acute leukemia that have not responded to standard therapy.
- What could go wrong
- This trial was withdrawn before enrolling any participants, so no data on safety or effectiveness exist. It is very early-stage research, and many such drugs never prove safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?